|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Appraisal of the Quality and Contents of Clinical Practice Guidelines for Hypertension Management in Chinese Medicine: A Systematic Review显示文摘Objective: To evaluate the quality and consistency of recommendations in the clinical practice guidelines(CPGs) for hypertension in Chinese medicine(CM). Methods: CM CPGs were identified from 5 electronic databases and hand searches through related handbooks published from January 1990 to December 2013. Three reviewers independently appraised the CPGs based on the Appraisal of Guidelines for Research and Evaluation(AGREE Ⅱ) instrument, and compared the CPGs' recommendations on CM syndrome pattern classification and treatment. Results: Five CM CPGs for hypertension were included. The quality score of the evidence-based(EB) guideline was higher than those of the consensus-based with no explicit consideration of evidence-based(CB-EB) and the consensus-based(CB) guidelines. Three out of five patterns in the CPGs were recommended by the EB guideline. Tianma Gouteng Formula(天麻钩藤复方) in the EB guideline was recommended mostly for hypertension patients with pattern of ascendant hyperactivity of Gan(Liver)-yang and pattern of yin deficiency with yang hyperactivity in the CPGs. Acupuncture and massage were recommended for Grade Ⅰ and Grade Ⅱ hypertension with severe symptoms weakening the quality of life in the EB guideline. For Grade Ⅰ and Grade Ⅱ hypertension, CM could be used alone, while for Grade Ⅲ hypertension, they should be used in combination with Western medicines. Conclusion: The quality of EB guideline was higher than those of CB and CB-EB CPGs in CM for hypertension and CM should be prescribed alone or combined with Western medicines based on the grade of hypertension. | YUWEN Ya HAN Xue-jie WENG Wei-liang ZHAO Xue-yao LIU Yu-qi LI Wei-qiang LIU Da-sheng WANG Yan-ping LU Ai-ping | 2018 | Chinese Journal of Integrative Medicine2018，24，7： | 8 |
| 2 | The add-on effect of a Chinese herbal formula for patients with resistant hypertension: study protocol for a pilot cohort study显示文摘BACKGROUND: Despite a recent American Heart Association(AHA) consensus statement emphasizing the importance of resistant hypertension(RH), its control is still a challenge for conventional medicine. The Chinese herbal formula, Qutan Huayu Fang, has been used effectively to assist antihypertensive agents in blood pressure control, but its effect for RH patients is still unclear. This pilot study aims to explore the effects of taking the formula in addition to antihypertensive medication in the management of RH.METHODS/DESIGN: A prospective cohort study will be conducted in two first-class hospitals of traditional Chinese medicine(TCM). Eligible RH patients will be classified as the experimental group(n = 100) and the control group(n = 100) based on the interventions they receive. Participants taking antihypertensive agents and the Chinese herbal formula will be in the experimental group and those taking antihypertensive agents alone will be in the control group. The whole study will last 24 weeks, including an 8-week observation and follow-up at 24 weeks. The primary outcomes, assessed against patient baseline conditions, will be the reduction of systolic blood pressure and diastolic blood pressure as well as changes in TCM symptoms and signs. These outcomes will be assessed at weeks 2, 4, 6, and 8. The reductions of blood pressure will also be assessed at week 24. Cardiac events and mortality rate will be secondary outcomes and will be assessed at weeks 8 and 24. Any adverse reactions will be recorded during the study. The causal inference method will be used to assess the effectiveness of the inclusion of TCM herbal medicine in the management of patients with RH.DISCUSSION: This study will determine whether the Chinese herbal formula is helpful for RH patients treated with antihypertensive agents and the findings will provide a basis for further confirmatory studies. | Ya Yuwen Yu-qi Liu Yan-ping Wang Jin-gang Dai Da-sheng Liu Yue-xi Wang Xue-jie Han | 2015 | Journal of Integrative Medicine2015，13，2： | 2 |
| 3 | Evaluation of the Conjoint Efficacy in Chinese Medicine with the Longitudinal Latent Variable Linear Mixed Model显示文摘临床的功效评估研究包含的中国药(厘米) 意味着病人们反复被测量,各,病人被几指示物在各个上测量的纵的 multivariate 测量修理了剖面图。尽管每指示物能与一个纵的线性混合模型一起独立被评估,当研究人员们在一个病人为几指示物对联合功效的变化给予特殊注意时,特别一起考虑所有端点是重要的。在这篇文章,我们把一个潜伏的可变线性混合模型介绍给 CM 联合功效评估并且讨论为什么并且怎么在临床的厘米功效评估研究分析纵的 multivariate 端点数据。它可以导致在厘米学习评估的联合功效的领域里使用如此的方法论的新卓见。并且与在 CM 理论的症候群和症状的定义,应用讨论带厘米症候群在未来评估的卓见。我们从 ischemic 击研究用厘米功效评估的一个例子说明这方法论。 | Dan-hui Yi 易丹辉 (11095) (21095) (31095) Yang Li 李 扬 (11095) (31095) (41095) Shu-xin Shao 邵淑新 (51095) Yan-ming Xie 谢雁鸣 (61095) Ya Yuwen 宇文亚 (61095) | 2013 | Chinese Journal of Integrative Medicine2013，19，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员